Drug profile · INN
osimertinib
TAGRISSO
osimertinib (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Associated with AstraZeneca.
Drug details — osimertinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 27
- Data quality
- 0.83
Quick answer
osimertinib (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Associated with AstraZeneca.
Key facts
Mechanism of action
Epidermal growth factor receptor erbB1 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment
The FDA has approved osimertinib (Tagrisso) for adjuvant treatment of early-stage NSCLC, marking a milestone for AstraZeneca and expanding treatment options. Learn about the clinical data, market impact, and investment implications.
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
This article delves into the latest EU guidelines and ESMO recommendations on treatment sequencing for non-small cell lung cancer (NSCLC), highlighting osimertinib's role.
EGFR Inhibitors Market Access in Europe: Launch Strategies & Challenges
This article delves into the market access strategies and challenges for EGFR inhibitors in Europe, crucial for advancing lung cancer therapies.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is osimertinib?
osimertinib (TAGRISSO) is a epidermal growth factor receptor erbb1 inhibitor. Associated with AstraZeneca.
What is the brand name for osimertinib?
TAGRISSO is a marketed brand name for osimertinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.